Prophylactic DLI for the Prevention of Relapse Post HSCT in Patients With High Risk Myeloid Malignancy

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2016
The trial will be conducted as a multicentre open label, randomised prospective phase II clinical trial in patients with high risk myeloid malignancies. The primary objective is to evaluate whether prophylactic donor lymphocyte infusions (DLI) delivered as part of a planned schedule improves the disease free survival of patients with myeloid malignancies.
Epistemonikos ID: 229eb16a366bec1b3419a312601d34e0cb1b4813
First added on: Jan 21, 2022